Related Experiment Video
Updated: Jan 12, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
A Fine Balance: Anticoagulation for Non-Valvular Atrial Fibrillation After Cerebral Amyloid Angiopathy-Related
Dane Turner1, Kanisha Kamadasala2, Bruce McGarity3
1Department of Cardiology, Royal Prince Alfred Hospital, Sydney Local Health District, Sydney, NSW, Australia; Department of Cardiology and General Medicine Bathurst Base Hospital, Western New South Wales Local Health District, Bathurst, NSW, Australia; Bathurst Clinical School, University of Western Sydney, Bathurst, NSW, Australia.
Abstract:
The management of anticoagulation in patients with non-valvular atrial fibrillation at high risk of bleeding complications can be challenging. One such group is elderly patients with previous intracranial haemorrhage secondary to cerebral amyloid angiopathy (CAA-ICH). These patients have a high rate of rebleeding, which can be predicted by features on cerebral magnetic resonance imaging. Common bleeding risk calculators, such as the HAS-BLED score, underestimate the bleeding event rate in patients with CAA-ICH due to poor patient representation in validation studies. Observational studies and subgroup analyses of small randomised controlled trials have failed to show conclusive evidence of benefit or harm with restarting anticoagulation after CAA-ICH. The results of larger, dedicated randomised controlled trials are eagerly awaited. An alternative to anticoagulation in patients with CAA-ICH and concomitant high ischaemic stroke risk is left atrial appendage closure, which has been shown to be effective in this subgroup. This narrative review will use a case to discuss the currently available evidence on this important topic, given our ageing population.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

